TY - JOUR
T1 - Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT
AU - Fuji, S.
AU - Takano, K.
AU - Mori, T.
AU - Eto, T.
AU - Taniguchi, S.
AU - Ohashi, K.
AU - Sakamaki, H.
AU - Morishima, Y.
AU - Kato, K.
AU - Miyamura, K.
AU - Suzuki, R.
AU - Fukuda, T.
N1 - Funding Information:
We thank the medical, nursing, data-processing, laboratory and clinical staffs at the participating centers for their important contributions to this study and their dedicated care of the patients. This study was supported in part by grants from the Ministry of Health, Labor and Welfare, Japan.
Publisher Copyright:
© 2014 Macmillan Publishers Limited.
PY - 2014/12/11
Y1 - 2014/12/11
N2 - To elucidate the impact of pretransplant body mass index (BMI) on the clinical outcome, we performed a retrospective study with registry data including a total of 12 050 patients (age ≥18 years) who received allogeneic hematopoietic SCT (HSCT) between 2000 and 2010. Patients were stratified as follows: BMI<18.5 kg/m 2, Underweight, n=1791; 18.5≤BMI<25, Normal, n=8444; 25≤BMI<30, Overweight, n=1591; BMI≥30, Obese, n=224. The median age was 45 years (range, 18-77). A multivariate analysis showed that the risk of relapse was significantly higher in the underweight group and lower in the overweight and obese groups compared with the normal group (hazard ratio (HR), 1.16, 0.86, and 0.74, respectively). The risk of GVHD was significantly higher in the overweight group compared with the normal group. The risk of non-relapse mortality (NRM) was significantly higher in the overweight and obese group compared with the normal group (HR 1.19 and HR 1.43, respectively). The probability of OS was lower in the underweight group compared with the normal group (HR 1.10, P=0.018). In conclusion, pretransplant BMI affected the risk of relapse and NRM after allogeneic HSCT. Underweight was a risk factor for poor OS because of an increased risk of relapse. Obesity was a risk factor for NRM.
AB - To elucidate the impact of pretransplant body mass index (BMI) on the clinical outcome, we performed a retrospective study with registry data including a total of 12 050 patients (age ≥18 years) who received allogeneic hematopoietic SCT (HSCT) between 2000 and 2010. Patients were stratified as follows: BMI<18.5 kg/m 2, Underweight, n=1791; 18.5≤BMI<25, Normal, n=8444; 25≤BMI<30, Overweight, n=1591; BMI≥30, Obese, n=224. The median age was 45 years (range, 18-77). A multivariate analysis showed that the risk of relapse was significantly higher in the underweight group and lower in the overweight and obese groups compared with the normal group (hazard ratio (HR), 1.16, 0.86, and 0.74, respectively). The risk of GVHD was significantly higher in the overweight group compared with the normal group. The risk of non-relapse mortality (NRM) was significantly higher in the overweight and obese group compared with the normal group (HR 1.19 and HR 1.43, respectively). The probability of OS was lower in the underweight group compared with the normal group (HR 1.10, P=0.018). In conclusion, pretransplant BMI affected the risk of relapse and NRM after allogeneic HSCT. Underweight was a risk factor for poor OS because of an increased risk of relapse. Obesity was a risk factor for NRM.
UR - http://www.scopus.com/inward/record.url?scp=84927174908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927174908&partnerID=8YFLogxK
U2 - 10.1038/bmt.2014.178
DO - 10.1038/bmt.2014.178
M3 - Article
AN - SCOPUS:84927174908
SN - 0268-3369
VL - 49
SP - 1505
EP - 1512
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 12
ER -
